PL362319A1 - Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists - Google Patents
Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonistsInfo
- Publication number
- PL362319A1 PL362319A1 PL36231902A PL36231902A PL362319A1 PL 362319 A1 PL362319 A1 PL 362319A1 PL 36231902 A PL36231902 A PL 36231902A PL 36231902 A PL36231902 A PL 36231902A PL 362319 A1 PL362319 A1 PL 362319A1
- Authority
- PL
- Poland
- Prior art keywords
- dementia
- treatment
- neurodegenerative diseases
- lhrh antagonists
- intermediate doses
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract 1
- 229960003230 cetrorelix Drugs 0.000 abstract 1
- 108700008462 cetrorelix Proteins 0.000 abstract 1
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL362319A1 true PL362319A1 (en) | 2004-10-18 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL36231902A PL362319A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (OSRAM) |
| EP (1) | EP1392348B1 (OSRAM) |
| JP (1) | JP2004529207A (OSRAM) |
| KR (1) | KR20040000446A (OSRAM) |
| CN (1) | CN1317030C (OSRAM) |
| AT (1) | ATE400287T1 (OSRAM) |
| AU (1) | AU2002310788B2 (OSRAM) |
| BG (1) | BG108339A (OSRAM) |
| BR (1) | BR0209290A (OSRAM) |
| CA (1) | CA2444876A1 (OSRAM) |
| CZ (1) | CZ20033167A3 (OSRAM) |
| DE (1) | DE60227507D1 (OSRAM) |
| DK (1) | DK1392348T3 (OSRAM) |
| ES (1) | ES2307760T3 (OSRAM) |
| HU (1) | HUP0400067A2 (OSRAM) |
| IL (1) | IL156777A0 (OSRAM) |
| MX (1) | MXPA03008666A (OSRAM) |
| NO (1) | NO20034322L (OSRAM) |
| NZ (1) | NZ544417A (OSRAM) |
| PL (1) | PL362319A1 (OSRAM) |
| PT (1) | PT1392348E (OSRAM) |
| RU (1) | RU2319501C2 (OSRAM) |
| SI (1) | SI1392348T1 (OSRAM) |
| SK (1) | SK14512003A3 (OSRAM) |
| UA (1) | UA80679C2 (OSRAM) |
| WO (1) | WO2002102401A1 (OSRAM) |
| ZA (1) | ZA200305326B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| PL360294A1 (en) | 2000-07-05 | 2004-09-06 | Yamanouchi Pharmaceutical Co.Ltd. | Propane-1,3-dione derivatives |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| RU2347781C2 (ru) * | 2004-06-04 | 2009-02-27 | Астеллас Фарма Инк. | Производное пропан-1,3-диона или его соль |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| EP2425846A1 (en) * | 2004-12-23 | 2012-03-07 | Voyager Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| NZ561387A (en) * | 2005-03-31 | 2010-07-30 | Astellas Pharma Inc | 1,3-dihydro-2H-benzimidazol-2-ylidene derivatives |
| KR20090071662A (ko) * | 2006-10-21 | 2009-07-01 | 애보트 게엠베하 운트 콤파니 카게 | 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도 |
| EP2197469A2 (en) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| WO2009039995A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Big gastrin i as a therapeutic agent |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| EP2307040B1 (en) * | 2008-05-29 | 2015-09-09 | Isr Immune System Regulation Ab | Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| CA2254769A1 (en) | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| NZ515460A (en) | 1999-05-14 | 2004-06-25 | Neurocrine Biosciences Inc | Imidazo- and pyrrolo[1,2-A]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| HK1047437B (en) | 1999-10-15 | 2005-12-16 | Neurocrine Biosciences, Inc. | Gonadotropin releasing hormone receptor antagonists and their related methods of use |
| US20030134863A1 (en) | 2000-04-13 | 2003-07-17 | Shuichi Furuya | Preventives/remedies for alzheimer's disease |
| PL360294A1 (en) * | 2000-07-05 | 2004-09-06 | Yamanouchi Pharmaceutical Co.Ltd. | Propane-1,3-dione derivatives |
-
2002
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1392348E (pt) | 2008-09-09 |
| UA80679C2 (en) | 2007-10-25 |
| EP1392348A1 (en) | 2004-03-03 |
| CA2444876A1 (en) | 2002-12-27 |
| RU2319501C2 (ru) | 2008-03-20 |
| EP1392348B1 (en) | 2008-07-09 |
| US7288517B2 (en) | 2007-10-30 |
| BR0209290A (pt) | 2004-07-13 |
| ZA200305326B (en) | 2003-07-30 |
| DK1392348T3 (da) | 2008-09-29 |
| IL156777A0 (en) | 2004-02-08 |
| MXPA03008666A (es) | 2004-10-15 |
| HUP0400067A2 (hu) | 2004-04-28 |
| ES2307760T3 (es) | 2008-12-01 |
| NO20034322D0 (no) | 2003-09-26 |
| SK14512003A3 (sk) | 2004-08-03 |
| RU2003134949A (ru) | 2005-02-10 |
| JP2004529207A (ja) | 2004-09-24 |
| CN1317030C (zh) | 2007-05-23 |
| CN1575185A (zh) | 2005-02-02 |
| DE60227507D1 (de) | 2008-08-21 |
| NZ544417A (en) | 2008-03-28 |
| BG108339A (bg) | 2004-11-30 |
| NO20034322L (no) | 2003-09-26 |
| US20020177556A1 (en) | 2002-11-28 |
| AU2002310788B2 (en) | 2007-04-05 |
| HK1072000A1 (en) | 2005-08-12 |
| CZ20033167A3 (cs) | 2004-08-18 |
| WO2002102401A1 (en) | 2002-12-27 |
| ATE400287T1 (de) | 2008-07-15 |
| KR20040000446A (ko) | 2004-01-03 |
| SI1392348T1 (sl) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156777A0 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists | |
| LU92854I2 (fr) | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil | |
| MY134906A (en) | Prevention and treatment of amyloidogenic disease | |
| GB0108592D0 (en) | Therapeutic agents | |
| MY136707A (en) | Thrombopoietin mimetics | |
| TNSN04113A1 (en) | 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| AU2003206413A8 (en) | Substituted amino carboxamides for the treatment of alzheimer's disease | |
| BG104686A (en) | Glycine transport inhibitors | |
| JO2207B1 (en) | Pharmaceutical radiological compounds to diagnose Alzheimer's disease | |
| EA200400352A1 (ru) | Органолептически приемлемые распадающиеся во рту композиции | |
| MY124786A (en) | Bis-arylsulfones | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| WO2003053136A3 (en) | Triple transgenic mouse model of alzheimer's disease | |
| BG105651A (en) | Vitronectin receptor antagonist | |
| DE60028928D1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt | |
| WO2002062383A3 (en) | Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases | |
| MXPA04000870A (es) | Uso de antagonistas-lhrh para mejorar la inmunidad mediada por celula-t. | |
| PL377110A1 (pl) | Zapobieganie i leczenie choroby Alzheimera | |
| MXPA03008406A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina. | |
| AU2002312797A1 (en) | Peptide for the diagnosis and therapy of alzheimer's disease | |
| HK1063639A (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| AU2002319451A1 (en) | Therapeutic strategies for prevention and treatment of alzheimer's disease | |
| YU9099A (en) | Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one for producting a pharmaceutical preparation for treatment of the alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |